Mayne Pharma faces potential class action over US antitrust case
ASX-listed generic drug maker Mayne Pharma is facing a possible shareholder class action over disclosures related to US price-fixing allegations against the ASX-listed company.
ASX-listed generic drug maker Mayne Pharma is facing a possible shareholder class action over disclosures related to US price-fixing allegations against the ASX-listed company.
For information on rights and reprints, contact subscriptions@lawyerly.com.au